Therapies that disrupt the pathway targeting IFN-γ, the IFN-γ receptor, the downstream signal JAK-STAT pathway, CXCL10 and its receptor CXCR3 are the most promising in vitiligo management. This evidence concerns the gene SOAT1 and vitiligo.